COL1A2 and atherosclerosis: Here, our in vivo data showed that therapeutic sclerostin antibody elevated serum levels of inflammatory cytokines and chemokines, and aggravated AA and atherosclerosis in Col1a2+/G610C.ApoE-/- mice with AngII infusion.